Swedish biotechnology company Cantargia AB (STO:CANTA) announced on Thursday a positive opinion from European authorities for orphan designation of nadunolimab (CAN04) for treatment of pancreatic cancer.
The positive opinion from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) was based on data from the ongoing CANFOUR trial, a phase I/IIa study in which CAN04 is being investigated in patients with advanced pancreatic ductal adenocarcinoma (PDAC) as first-line combination with gemcitabine and nab-paclitaxel.
The European Commission is now expected to grant the orphan designation within 30 days.
CAN04 was granted orphan drug designation for treatment of pancreatic cancer by the US Food and Drug Administration (FDA) in September 2021.
An interleukin-1 receptor accessory protein (IL1RAP)-binding antibody, CAN04 is currently being investigated in multiple clinical trials evaluating combination with chemotherapy regimens in various forms of cancer, including PDAC, the most common form of pancreatic cancer.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval